Tedavinin üçüncü basama¤> yaklafl>k yedinci gün civar>nda bafllar, bu dönemde hasta
klinik olarak istikrarl>d>r ve atefli yoktur. Bu noktada hastan>n hastanede yatmas>n>n tek
nedeni parenteral antibiyotik kullan>m>na devam edilmesidir. Ancak pek çok hastada te-
davi, günlük intravenöz dozla ya da oral antibiyotikler ile de¤ifltirilerek hastane d>fl>nda
uygulanabilir. Antibiyotik tedavisini modlar> ve uygulama s>kl>¤>n> de¤ifltirerek ayarla-
mak, etkili ve sorumlu bir flekilde maliyetin azalt>lmas> için temel basamakt>r.
Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-
positive infections. Expert Opin Investig Drugs. 2003;12:379399.
Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending
single intravenous doses of oritavancin administered to healthy human subjects. Diagn
Microbiol Infect Dis. 2004;50:95102.
Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics,
safety and efficacy. Drugs. 2004;64:19972020.
Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant
Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob
Chemother. 2003;52:864868.
Bronson JJ, Barrett JF. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and
cephem antibacterials in clinical development. Curr Med Chem. 2001;8:17751793.
Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-
modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and
vancomycin-resistant enterococci. J Antimicrob Chemother. 2002;50:731734.
Buynak JD. The discovery and development of modified penicillin- and cephalosporin-derived
beta-lactamase inhibitors. Curr Med Chem. 2004;11:19511964.
Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to
drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:9941000.
Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus--
New York, 2004. MMWR Morb Mortal Wkly Rep. 2004 Apr 23;53(15):322323.
Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in
Staphylococcus aureus. J Clin Microbiol. 2003;41:514.
Dalhoff A, Thomson CJ. The art of fusion: from penams and cephems to penems. Chemotherapy.
2003;49:105120.
Decousser JW, Pina P, Picot F, et al. Comparative in vitro activity of faropenem and 11 other
antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France. Eur J
Clin Microbiol Infect Dis. 2003;22:561565.
Delgado G Jr, Neuhauser MM, Bearden DT, et al. Quinupristin-dalfopristin: an overview.
Pharmacotherapy. 2000;20:14691485.
Deshpande L, Rhomberg PR, Fritsche TR, et al. Bactericidal activity of BAL9141, a novel
parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
Diagn Microbiol Infect Dis. 2004;50:7375.
Gallagher JC, MacDougall C, Ashley ES, et al. Recent advances in antifungal pharmacotherapy
for invasive fungal infections. Expert Rev Anti Infect Ther. 2004;2:253268.
Graninger W, Zeitlinger M. Clinical applications of levofloxacin for severe infections.
Chemotherapy. 2004;50 suppl 1:1621.
Hoellman DB, Lin G, Ednie LM, et al. Antipneumococcal and antistaphylococcal activities of
ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob
Agents Chemother. 2003;47:11481150.
78
·
Genel T>pta Yenilikler